Title: METHODS OF USING A MAJOR HISTOCOMPATIBILITY...
Inventors: Taylor et al.
Serial No.: Not yet determined (docket # P-CE 5187)

										1/6										
Roforence	DOIDIOIDI	This work based on Genbank 197183		Kikuli et al., <i>Genomics</i> 42:422-435	(1997). This work bused on ochionin	004401	608 10 600-250-903; Corringion & Jean,	HUMMAN MOIBEUIAI VEIIBIICS 3:110 (1334)			Eligou et al., <i>Nucleic Acids Res.</i>	(1881) (817:81)	Sugaya et al., Gene 189.235-244 (1997)		Milner & Campbell, Immunogenetics	36:351-367 (1997)	GDB id GOO-133-162, AFM142xh6, Gyapay	et al., <i>Mature Genetics 1:</i> 246-339 (1994)	This work based on GenBank 715025	
Enzymo	רוונאווופ										Ddel		<del></del> -		Ncol		······································			
Nirootion Enzymo		forward	reverse	forward	reverse		forward	reverse			forward	reverse	forward	reverse	forward	reverse	forward	reverse	forward	reverse
SEG	 	-	2	ന	4		ഹ	ص			7	8	6	10	1	12	13	14	15	9
Dimor		HEC CTG TAA TCC CAG CTA CTC AAT CG	GGG AGA CTT AAA CAG CAG AAA TGT	TET TCG GGA TCA TTT CAG TAA TCT	GGG ATC CGC TGT AAC TCT		HEX GGA CAA TAT TTT GCT CCT GAG G	GCT TTG ATC TCC CCC CTC			GAG CTC GGG AGT GAG GCA GAA CAG	TGA GGT GTG TTC ATT AGT CAA CTC	FAM CGT CTC TAT TTG GGC AGT GAG	GGC CGA GGA GGA AGA AGA	CCG GAT CCC ATA GGC CTC AGA GAA CC	GTA ACT TAG ATT CAG GTC TGG	FAM ACC AAA CTT CAA ATT TTC GG	GCA ACT TTT CTG TCA ATC CA	HEX GGA GCT AAA AGT TCT AAC TC	TGT CTC AAA ATA TTA ATG TG
	Type Location Landmarks					HLA-DPB1			HLA-DQB1	HLA-DRB1										
	Location	0.10		0.22	————	0.35	0.6		0.75	0.83	0:		1.2		1.6		1.1		1.89	
	<b>J</b>	SEE .		SE			SIII				SIID		SⅢ	-	S		<b>E</b>		SE	
	Marker	Tapasin		HKE 6			Tool				HLA-DRA		Notch4		HSP-HOM		068273		But 2	

from the part I goed I see that I will be the man with the part of the part of

Figure 1A

And I had been the sent that the first that the fir

Title: METHODS OF USING A MAJOR HISTOCOMPATIBILITY...
Inventors: Taylor et al.
Serial No.: Not yet determined (docket # P-CE 5187)

				<del></del>	***************************************	$\neg \tau$			2/	<u>.</u>	Т		Т	·		$\overline{}$		<b>8</b>	$\neg$
Reference	DeBagy et al., Human Immunol. 42:9-14	(1994). IIIIS WUIK DUSCU VII OCIIDUIIN OUUSLI	Nedospasoy et al., //mmuno/ 147:1053-1059	(1991); Uddioya et al., <i>behomics</i> ib:180-180 (1933)	Nedospasov et al., supra, (1991);	Udalova el al., <i>supra,</i> (1993)		Nedospasov et al., <i>supra</i> , (1991);	Udalova el al., <i>supra</i> , (1993)	Nedospasov et al., supra, (1991);	Udalova el al., <i>supra</i> , (1993)	Nedospasov et al., supra, (1991);	Udalova el al., <i>supra</i> , (1993)	Mituki et al., <i>Diabetes</i> 47:263-269 (1997)				Tamiya et al., <i>Tissue Antigens</i> 51:337-346 (1998)	
Enzyme	PYUIT			<u>.</u>				<del></del>											
Direction Enzyme	forward	reverse	forward	reverse	forward	reverse		forward	reverse	forward	reverse	forward	reyerse	forward	reverse			forward	reverse
SEO. ID NO.	11	18	19	20	21	22		23	24	25	26	11	28	29	30			31	32
Primer	TAG TAA TIT GIT GGG TGA ATG ACA	CAC ACT GCC ACT CCT CAG AT	TET CAT AGT 666 ACT CTG TCT CCA AAG	1		TGA GAC AGA GGA TAG GAG AGA CAG		HEX 66T TTC TCT 6AC T6C ATC TTG TCC	TCA TGG GGA GAA CCT GCAGAG AA	HEX CCT CTC TCC CCT GCA ACA CAC A	GCC TCT AGA TTT CAT CCA GCC ACA	HEX GTG TGT GTT GCA GGG GAG AGA G	GCA CTC CAG CCT AGG CCA CAG A	TET ACA ATG GAC ACT TGG GTT ACT	AAT GAG ATG CCA CCT GAA A			TET TTA TCT ACT TAT AGT CTA TCA CGG	GGC TTG ACT TGA AAC TCA GAG ACC
Marker Type Location Landmarks							<b>IN</b>	INFB	-							HLA-B	HLA-C		
Location	1.84		1.84		1.84			1.86		1.86		1.86		2.1		2.1	2.2	2.4	
Type	SIID		ms		SIII			SIII		SIII		SIII		SIII				£	
Marker	ISTI		INEG		]Fe			TWFC		TE-		TRE		MICA				C2-4-4	

time that then H. than that

Title: METHODS OF USING A MAJOR HISTOCOMPATIBILITY... Inventors: Taylor et al.

Serial No.: Not yet determined (docket # P-CE 5187)

3/5

Mirker	Tyne	Incution	Marker Tvne Incation Inadmarks	Primer	S.E.	SEQ. Direction Enzyme	Enzyme	Reference
	SIII	ms 2.5-2.7		AC TGG CTA T	33	33 forward		Tuliani & Hobbs, Am / Hum Genel. 46:963-969
				CTG GGC AAC AGA GCG AGC TCC GTC T	34	reverse		(1990); This work based on Genbank XUU/34
C3-2-11	SIII	2.9		FAM TCC TTA CAG CAG AGA TAT GTG G	35	35 forward		Tamiya et al., <i>supra</i> , (1998)
				AGA TGG CAT TTG GAG AGT GCA G	36	reverse		
and the state of t		3.4	H.A-A					
D6S510	SIII	<u> </u>		FAM CAA CAC ACT GAT TTC CAT AGC	37	forward		6DB id 600-249-443; Gandon et al.,
				AAT GGG CTA CTA CTT CAC ACC	38	reverse		Human Holecular Genetics 3:1210 (1994)
M0611	SE	3.9		HEX GAA ATG TGA GAA TAA AGG AGA	33	forward		Roth et al., Human Immunol. 43:216-282
				GAT AAA GGG GAA CTA CTA CA	40	reverse		(1995)


Title: METHODS OF USING A MAJOR HISTOCOMPATIBILITY... Inventors: Taylor et al.
Serial No.: Not yet determined (docket # P-CE 5187)

4/5

## Association of MHC markers in the Jewish case-control panel

Marker	Number of alleles	p	Allele	Allele Frequency					
	uliele9			CD	Control				
Tapasin	12	0.88							
HKE6	9	0.90							
Tap1	9	0.44							
HLA-DRA	2	0.021		•					
Notch4	7	0.011	2	35%	25%				
HSP-HOM	2	0.12							
D6S273	7	0.84							
Bat2	12	0.12							
LST1	2	0.30							
TNFd	6	0.34			-				
TNFe	3	0.23							
TNFc	2	0.33							
TNFa	13	0.37							
TNFb	5	0.78							
MICA	11	0.87							
C2-4-4	11	0.70							
TUBB	5	0.014	4	5%	37%				
<b>C</b> 3-2-11	20	0.92							
D6S510	9	0.79							
MOG11	10	0.31							

Figure 2



And I have been to the form that the first that the